CanSino Biologics Inc (CJH) — Capital Reinvestment Ratio

Latest as of December 2021: 0.35x

CanSino Biologics Inc (CJH) has a Capital Reinvestment Ratio of 0.35x as of December 2021, meaning it reinvests 0% of its operating cash flow (€806.73 Million) in capital expenditures (€284.07 Million). Check CanSino Biologics Inc tangible equity quality to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.35x
Capex / Operating Cash Flow

Operating Cash Flow

€806.73 Million
EUR

Capital Expenditures

€284.07 Million
EUR

Data as of

Dec 2021
Most recent filing

CanSino Biologics Inc Capital Reinvestment Ratio (2021–2025)

This chart tracks CanSino Biologics Inc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see CanSino Biologics Inc (CJH) cash flow conversion.

Annual Capital Reinvestment Ratio for CanSino Biologics Inc (2021–2025)

Year-by-year Capital Reinvestment Ratio for CanSino Biologics Inc from 2021 to 2025. See cash generation quality of CanSino Biologics Inc to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2025 3.13x €77.86 Million €243.90 Million ▲ +433.8%
2021 0.59x €2.05 Billion €1.20 Billion —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow